Researchers reported in Nature Metabolism that cell-specific DNA methylation programs help drive gene expression differences between pancreatic alpha and beta cells across the lifespan and in type 2 diabetes biology. The study mapped methylation landscapes and linked regulatory patterns to distinct transcriptional outputs in relevant endocrine cell types. The work focuses on methylation “where it matters” at a cell-type resolution level, rather than treating pancreas methylation signals as uniform. By anchoring regulatory differences to alpha versus beta cells, the study provides a more precise framework for interpreting how epigenetic variation may contribute to diabetes risk and progression. The findings support a growing push to connect epigenetic regulation to actionable mechanisms, potentially improving target selection and biomarker development for diabetes subpopulations.